News

Do you want to help support student interns? Apply Now!

As students have shown great interest in the upcoming STEM2VA Summer Internship Program, we at VA Bio-Connect want to continue to invite employers to register as host sites for this great opportunity in providing experiential learning to those interested in the life sciences. With an application close date of Jan 31, 2022. There were over 1000 students interested, with over 350 submissions by the closing date. Students have shown interest in all regions across the Commonwealth of Virginia, with specific student interests in bioengineering (180), medical devices (194), and pharmaceuticals (210) respectively.

 

Currently, over 25 employers including; Atelerix Life Sciences Inc. (Charlottesville/Albemarle), ReAlta Life Sciences and LifeNet Health (Coastal VA), Athari Bio Sciences, Inc. and Polaris Genomics (Northern VA), Tympanogen (Richmond), CytoRecovery (Roanoke), and many others across Virginia have registered to host student interns. Employers are encouraged to register as application reviews have just begun and will continue to mid-March to ensure student award letters are presented to the 100 candidates by March 31, 2022. This extraordinary experience is great for the next generation of life science professionals. If you are interested in hosting a student intern, please register here to receive your link to begin reviewing applications.

Any questions you have before registering, please contact VA Bio-Connect Admin at vbcintern@vabio.org for assistance. We look forward to matching you with qualified candidates.

Recent News

06/12/2024

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland. The scope of the agreement encompasses the development of novel topical formulations of Rapamycin (sirolimus) as potential

06/11/2024

KeViRx, Inc. Awarded $1.99 Million

KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury

05/31/2024

Virginia Catalyst Announces Round 17 of Grant Funding

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 16 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The mission of the Catalyst